<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02033525</url>
  </required_header>
  <id_info>
    <org_study_id>XCEL-MEN-01</org_study_id>
    <secondary_id>2011-006270-13</secondary_id>
    <nct_id>NCT02033525</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stromal Cells for Degenerative Meniscus Injury</brief_title>
  <official_title>A Phase I-IIa Safety and Efficacy Pilot Clinical Trial of Intraarticular Administration of Autologous Mesenchymal Cells for Meniscus Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitari Quirón Dexeus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministerio de Sanidad, Servicios Sociales e Igualdad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present proposal has the objective to assess whether the addition of autologous ex vivo&#xD;
      expanded mesenchymal stromal cells (XCEL-M-ALPHA) to the conventional meniscal injury&#xD;
      rehabilitation program is contributing in creating the proper healing environment for the&#xD;
      meniscus repair. For this purpose, 20 patients will be randomized (10 per group) to one of&#xD;
      the two treatment arms (rehabilitation + xcel-m-alpha or rehabilitation alone) . The&#xD;
      conduction of this clinical trial will, in addition of having the aim of improving the&#xD;
      patient's quality of life, contribute to consolidate an emerging new type of therapy which is&#xD;
      still under development.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, unicentric, randomized, open-label, single-dose, two-arm, blinded&#xD;
      assessor pilot study in which 20 patients with degenerative meniscus injury grade 3 (Crues et&#xD;
      al.) will enter the study with the primary objective of assessing the efficacy of the&#xD;
      treatment by VAS of pain at 12 month. Secondary objectives are to evaluate the safety and&#xD;
      efficacy through imaging procedures and clinical questionnaires (IKDC, KOOS, Lysholm and&#xD;
      SF-36.&#xD;
&#xD;
      Patients will be randomized to one of the two treatment arms (XCEL-M-ALPHA and standard&#xD;
      rehabilitation program or standard rehabilitation program alone). Thereafter, patients will&#xD;
      be followed for 12 months.&#xD;
&#xD;
      Imaging assessment will be performed by an independent blinded radiologist.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2014</start_date>
  <completion_date type="Actual">May 2, 2017</completion_date>
  <primary_completion_date type="Actual">May 2, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS for pain</measure>
    <time_frame>12 month</time_frame>
    <description>Visual analogue scale (VAS) for pain at 12 month follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>12 month</time_frame>
    <description>Safety will be assessed by collecting adverse events, physical exam, laboratory tests, and vital signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy by MRI</measure>
    <time_frame>6 and 12 month</time_frame>
    <description>Efficacy will be assessed by qualitative and quantitative changes of the meniscus and articular cartilage by imaging procedures (MRI) at 6 and 12 month follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS for pain</measure>
    <time_frame>1, 3 and 6 month</time_frame>
    <description>Visual analogue scale (VAS) for pain at 1, 3 and 6 month follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy by clinical questionnaires</measure>
    <time_frame>3, 6 and 12 month</time_frame>
    <description>IKDC, KOOS and Lysholm functionality test and SF-36 quality of life at 3, 6 and 12 month follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Meniscal Injury</condition>
  <arm_group>
    <arm_group_label>XCEL-M-ALPHA and standard rehabilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard rehabilitation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard rehabilitation program</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XCEL-M-ALPHA and standard rehabilitation</intervention_name>
    <description>Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)</description>
    <arm_group_label>XCEL-M-ALPHA and standard rehabilitation</arm_group_label>
    <other_name>XCEL-M-ALPHA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rehabilitation</intervention_name>
    <description>Standard rehabilitation program</description>
    <arm_group_label>standard rehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient between 40 and 60 years of age&#xD;
&#xD;
          -  Degenerative meniscus injury grade 3 (Crues et al.)&#xD;
&#xD;
          -  Indication of conservative treatment&#xD;
&#xD;
          -  Normal alignment of the knee (between 3º varus and 10 º valgus)&#xD;
&#xD;
          -  Patient is able to follow a rehabilitation program&#xD;
&#xD;
          -  Informed consent given by the patient in writing&#xD;
&#xD;
          -  Patient is able to understand the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Traumatic meniscus injury&#xD;
&#xD;
          -  Surgical intervention to the affected knee&#xD;
&#xD;
          -  Local or systemic infection&#xD;
&#xD;
          -  Intraarticular treatment of the affected knee with steroids or hyaluronic acid within&#xD;
             the past 3 months&#xD;
&#xD;
          -  Significant abnormal laboratory tests that contraindicates participation in the trial.&#xD;
&#xD;
          -  Pregnant women or intend to become pregnant or breast-feeding&#xD;
&#xD;
          -  Neoplastic process within the previous 5 years or without complete remission.&#xD;
&#xD;
          -  The patient is wearing a pacemaker, allergy to contrast, severe renal insufficiency or&#xD;
             any other condition that contraindicates the magnetic resonance using contrast.&#xD;
&#xD;
          -  Other pathologic conditions or circumstances that difficult participation in the study&#xD;
             according to medical criteria&#xD;
&#xD;
          -  Legally dependant patient.&#xD;
&#xD;
          -  The patient does not accept to be followed-up for a period that could exceed the&#xD;
             clinical trial length&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Carles Monllau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICATME-Hospital Quiron Dexeus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICATME-Hospital Quiron Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.bancsang.net/en/index.html</url>
    <description>Blood and tissue bank of Catalonia</description>
  </link>
  <link>
    <url>http://www.icatme.com/</url>
    <description>Fundación ICATME (Spanish only)</description>
  </link>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 8, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2014</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Meniscal Injury</keyword>
  <keyword>Degenerative meniscus</keyword>
  <keyword>Meniscus injury</keyword>
  <keyword>Meniscal injury</keyword>
  <keyword>Mesenchymal stromal cells</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>Advanced Therapy</keyword>
  <keyword>Bone marrow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

